ATE287270T1 - Verfahren zur herstellung eines arzneimittels zur behandlung des sekundärimmunmangels - Google Patents

Verfahren zur herstellung eines arzneimittels zur behandlung des sekundärimmunmangels

Info

Publication number
ATE287270T1
ATE287270T1 AT95942931T AT95942931T ATE287270T1 AT E287270 T1 ATE287270 T1 AT E287270T1 AT 95942931 T AT95942931 T AT 95942931T AT 95942931 T AT95942931 T AT 95942931T AT E287270 T1 ATE287270 T1 AT E287270T1
Authority
AT
Austria
Prior art keywords
producing
immune deficiency
medicinal product
secondary immune
treating secondary
Prior art date
Application number
AT95942931T
Other languages
English (en)
Inventor
John W Hadden
Original Assignee
Univ South Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ South Florida filed Critical Univ South Florida
Application granted granted Critical
Publication of ATE287270T1 publication Critical patent/ATE287270T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/59—Lectins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT95942931T 1994-11-17 1995-11-16 Verfahren zur herstellung eines arzneimittels zur behandlung des sekundärimmunmangels ATE287270T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34164594A 1994-11-17 1994-11-17
PCT/US1995/015492 WO1996015808A1 (en) 1994-11-17 1995-11-16 Method for making a medicament for treating secondary immunodeficiency

Publications (1)

Publication Number Publication Date
ATE287270T1 true ATE287270T1 (de) 2005-02-15

Family

ID=23338440

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95942931T ATE287270T1 (de) 1994-11-17 1995-11-16 Verfahren zur herstellung eines arzneimittels zur behandlung des sekundärimmunmangels

Country Status (11)

Country Link
US (1) US5698194A (de)
EP (1) EP0789588B1 (de)
JP (4) JP4440342B2 (de)
AT (1) ATE287270T1 (de)
AU (1) AU694304B2 (de)
CA (1) CA2205430C (de)
DE (1) DE69533941T2 (de)
DK (1) DK0789588T3 (de)
ES (1) ES2236719T3 (de)
PT (1) PT789588E (de)
WO (1) WO1996015808A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3497607B2 (ja) * 1995-05-26 2004-02-16 オリンパス株式会社 接眼光学系及びそれを用いた画像表示装置
ATE476496T1 (de) * 1996-03-04 2010-08-15 Calyx Bio Ventures Inc Modifizierte schnellvermehrungsmethode ('modified-rem') zur in vitro vermehrung von t-lymphozyten
ATE229342T1 (de) * 1997-02-21 2002-12-15 Vlaams Interuniv Inst Biotech Verwendung von interleukin-15
WO1999020788A1 (en) * 1997-10-17 1999-04-29 University Of South Florida Method to diagnose and monitor cellular immune deficiencies
AU760486B2 (en) * 1999-10-13 2003-05-15 Incyte Genomics, Inc. Multiplex cytokine analysis
EP1318834A2 (de) * 2000-09-12 2003-06-18 Genetrol Biotherapeutics, Inc. Zusammensetzung, die eine mischung von menschlichen zytokinen enthält, sowie verfahren für ihre herstellung
US20020150541A1 (en) * 2000-09-12 2002-10-17 Gene Trol Biotherapeutics, Inc. Compositions comprising mixtures of therapeutic proteins and methods of producing the same
US20030129162A1 (en) * 2000-09-12 2003-07-10 Lau Allan S. Compositions comprising mixtures of therapeutic proteins and methods of producing the same
AU2002232560A1 (en) 2000-10-27 2002-05-06 Immuno-Rx, Inc Vaccine immunotherapy for immune suppressed patients
US20070031372A1 (en) * 2004-08-05 2007-02-08 Hadden John W Vaccine immunotherapy for immune suppressed patients
US20060194242A1 (en) * 2000-10-27 2006-08-31 Hadden John W Immunotherapy for immune suppressed patients
US20070154399A1 (en) * 2000-10-27 2007-07-05 Hadden John W Immunotherapy for immune suppressed patients
US20070025958A1 (en) 2000-10-27 2007-02-01 Hadden John W Vaccine immunotherapy
US7182942B2 (en) 2000-10-27 2007-02-27 Irx Therapeutics, Inc. Vaccine immunotherapy for immune suppressed patients
AU2002342151B2 (en) * 2001-10-26 2007-07-19 Immuno-Rx, Inc. Immunotherapy for reversing immune suppression
US20050002899A1 (en) * 2003-07-03 2005-01-06 Eyal Talor Method of pre-sensitizing cancer prior to treament with radiation and/or chemotherapy and a novel cytokine mixture
US6896879B2 (en) * 2003-07-03 2005-05-24 Cel-Sci Corporation Method of pre-sensitizing cancer prior to treatment with radiation and/or chemotherapy and a novel cytokine mixture
WO2005065079A2 (en) * 2003-11-10 2005-07-21 Angiotech International Ag Medical implants and fibrosis-inducing agents
CN101005760A (zh) * 2004-06-04 2007-07-25 塞尔-赛公司 改变cd4/cd8和进入肿瘤的单核细胞浸润液的方法
EP1773395B1 (de) * 2004-07-30 2011-06-22 Cel-Sci Corporation Verfahren zum verwalten von cholesterin mit einer serums- und mitogenfreien zytokin-mischung
US20060257357A1 (en) * 2005-05-10 2006-11-16 Cel-Sci Corporation Method for modulating HLA class II tumor cell surface expression with a cytokine mixture
JP5563472B2 (ja) 2007-11-28 2014-07-30 アイ アール エックス セーラピューティクス， インコーポレイテッド 免疫学的効果を増大させる方法
CA2758834C (en) * 2008-04-14 2017-11-07 Irx Therapeutics, Inc. Primary cell derived biologic modified manufacturing process
CA3017298C (en) 2009-05-15 2021-09-28 Irx Therapeutics, Inc. Compositions comprising primary cell-derived biologics for enhancing immune responses in patients
ES2667476T3 (es) 2009-12-08 2018-05-11 Irx Therapeutics, Inc. Método para invertir la supresión inmunitaria de células de Langerhans

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4390623A (en) * 1980-10-02 1983-06-28 Hooper Trading Company Serum-free and mitogen-free T-cell growth factor and process for making same
US4464355A (en) * 1981-03-26 1984-08-07 Hooper Trading Co. Serum-free and mitogen-free T-cell growth factor and process for making same
US4448879A (en) * 1981-03-26 1984-05-15 Hooper Trading Company High yield process for in vitro production of serum-free and mitogen-free interleukin-2
SE8801426D0 (sv) * 1988-04-15 1988-04-15 Ulf Rothman Forfarande och medel for blodbehandling

Also Published As

Publication number Publication date
JP2009209164A (ja) 2009-09-17
AU4411196A (en) 1996-06-17
JP2005245455A (ja) 2005-09-15
US5698194A (en) 1997-12-16
MX9703626A (es) 1998-12-31
JP2007236395A (ja) 2007-09-20
ES2236719T3 (es) 2005-07-16
PT789588E (pt) 2005-05-31
CA2205430C (en) 2001-09-04
AU694304B2 (en) 1998-07-16
DK0789588T3 (da) 2005-05-30
EP0789588A1 (de) 1997-08-20
DE69533941T2 (de) 2005-12-29
EP0789588B1 (de) 2005-01-19
CA2205430A1 (en) 1996-05-30
JPH10510147A (ja) 1998-10-06
EP0789588A4 (de) 2001-11-28
JP4440342B2 (ja) 2010-03-24
WO1996015808A1 (en) 1996-05-30
DE69533941D1 (de) 2005-02-24

Similar Documents

Publication Publication Date Title
ATE287270T1 (de) Verfahren zur herstellung eines arzneimittels zur behandlung des sekundärimmunmangels
AU7769887A (en) Apparatus and methods of culturing motile microorganisms
EP0239697A3 (en) Apparatus for growing tissue cultures in vitro
CA2087525A1 (en) Adoptive immunotherapy with interleukin-7
DE69333433D1 (de) Verfahren zur in vitro kultivierung dendritischer vorläuferzellen und deren verwendung zur immunogen herstellung
BG49717A3 (bg) Метод за получаване на хирудин
AU4277689A (en) Process for producing cultured epidermal sheet, product and method of use
KR960009482B1 (en) Method for preserving transplantable sheets of epithelium cultured in vitro
ES500122A0 (es) Procedimiento para preparar un producto con actividad de ti-po fibronectina
AU1394888A (en) Plant gum material and use thereof in food products
EP0340783A3 (en) Apparatus for culturing animal cells, method of culturing thereof and diagnostics of the culture
FR2620131B1 (fr) Procede de production de carotenoides et notamment d'astaxanthine par culture de microalgues et dispositif pour la mise en oeuvre du procede
EP0205387A3 (en) Human monocytes cultured in suspension in serum-free medium
EP0362408A4 (en) Method of culturing plant organs and culture vessel therefor
Mayyasi et al. Cultivation of L strain (Earle) mouse cells in bacteriological media combined with horse serum
DE3364657D1 (en) Process and apparatus for culture of microorganisms using oxygen-enriched gas
IL88863A0 (en) Method and system for in vitro culture of bovine embryos
EP0201800A3 (en) A cholesterol-rich fraction, process therefor and use thereof in cell culture
GB2233666B (en) Microbacterium strain 851, culture media for same and production of single cell nutrient solution.
JPS6437282A (en) Method and apparatus for culture of microorganism
PT83368A (en) Process for propagating microorganisms in vivo by using cell lines which lack human class ii histocompatibility antigens
EP0299067A4 (de) Zuchtmedium für pflanzen.
GR3031236T3 (en) Process for the preparation of pilocarpine.
PL239589A1 (en) Agent for use reproduction process of cultivable plants by means of tissue culture in vitro and method of increasing reproduction rate of cultivable plants by means of tissue culture in vitro
PL285546A1 (en) Biological culture medium for cell cultures and method of culturing human keratocytes as well as proteinous concentrate

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0789588

Country of ref document: EP